About Us
About Noxopharm
CEO's Message
Management Team
Board of Directors
Scientific Advisors
Our Network
Pharmorage
ESG Commitment
Technology
Technology Platforms
Chroma™
Sofra™
mRNA Vaccines
Autoimmune Disease
Clinical Trials
Publications
Investor Centre
Share Price
Presentations & Interviews
Annual Reports
Financial Reports
ASX Announcements
Corporate Governance
Investor Fact Sheet
Share Registry Information
Contact Us
Contact Us
Partnering
Working at Noxopharm
ASX Announcements Email Alerts
Investor Centre
Investor Centre
>
ASX Announcements
Share Price
Presentations & Interviews
Annual Reports
Financial Reports
ASX Announcements
Corporate Governance
Investor Fact Sheet
Share Registry Information
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
19 Feb 2021
Option Underwriting Agreement to Secure Funds
19 Feb 2021
Cleansing Notice
19 Feb 2021
Appendix 2A
16 Feb 2021
Noxopharm CEO Letter to Shareholders February 2021
16 Feb 2021
Appendix 4D and Half Year Financial Report
15 Feb 2021
Cleansing Notice
15 Feb 2021
Appendix 2A
15 Feb 2021
LuPIN Survival Outcome Confirmed by Conference Presentation
9 Feb 2021
Major Survival Benefit in Prostate Cancer Patients Announced
5 Feb 2021
Cleansing Notice
Previous
1
2
3
4
5
6
7
8
9
10
11
Next
